India, Dec. 12 -- Drugmaker Novo Nordisk on Friday launched its blockbuster diabetes drug Ozempic in India, at a time when treatment demand for diabetes and weight loss is accelerating across the country.

The weekly injectable has been priced at Rs 2,200 for the 0.25 mg starter dose, according to India Today.

The launch comes amid growing global momentum around GLP-1 therapies, which have reshaped treatment approaches for diabetes and obesity. To address the escalating obesity epidemic, affecting over 1 billion people, the World Health Organization (WHO) recently released its first-ever guideline on the use of GLP-1 therapies for obesity, now recognized as a chronic and relapsing disease.

Obesity was linked to 3.7 million deaths worldw...